Celltrion USA Receives U.S. FDA Approval for Biosimilar Vegzelma for 6 Types of Cancer

 

• Vegzelma® is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA
• Vegzelma® offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option
• The approval is based on totality of evidence with no clinically meaningful differences in efficacy or safety with the reference product Avastin® (bevacizumab)

https://www.businesswire.com/news/home/20220927006146/en/Celltrion-USA-Receives-U.S.-FDA-Approval-for-its-Oncology-Biosimilar-Vegzelma%C2%AE-bevacizumab-adcd-for-the-Treatment-of-Six-Types-of-Cancer